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INTRODUCTION
Brain metastasis (BM) occurs in 10-30% of all adult cancer patients. 1) BM from esophageal carcinoma (EC) has been considered relatively rare, with some reports indicating BM from EC in 1.4-1.7% of cases. [2] [3] [4] A few cases have been reported recently, but most have been single cases. [5] [6] [7] [8] [9] Advances in neuroimaging and increased survival of these patients have led to more frequent and earlier detection of BM. 10) To date, few reports regarding the occurrence and clinical features of BM after chemoradiotherapy (CRT) for EC have been published. This study examined cumulative incidence, risk factors and clinical characteristics of BM after CRT for EC.
MATERIALS AND METHODS

Patients
Between September 2002 and March 2008, a total of 441 patients (396 men, 45 women) with EC were diagnosed and treated with radiotherapy (RT) at Shizuoka Cancer Center Hospital. Of these 441 patients, BM was not detected among all 50 patients treated with RT alone, so we focused on the rest of 391 patients (352 men, 39 women) treated with CRT in the present study. Median age was 65 years (range, 40-86 years). Patient backgrounds are summarized in Table 1 . Tumor stages were classified according to the 6th TNM classification of the International Union Against Cancer (UICC). 11) Among the subjects, 162 patients showed distant metastases and were classified as stage IV, comprising 137 patients with distant lymph node metastasis, 24 patients with lung metastasis, 20 patients with liver metastasis, 8 patients with bone metastasis, 2 patients with adrenal metastasis, and 8 patients with other metastases. Presence of more than one metastatic site was identified in 24 patients (15%).
Multiple primary neoplasms were seen in 84 patients. These were diagnosed simultaneously in 55 patients, previously in 25 patients and subsequently in 1 patient. Three patients showed not only detection of EC and another cancer at the same time, but also a third cancer at another time. Among 84 patients, 3 had quadruple primary neoplasms, 16 had triple, and 65 had double. Sites of multiple primary neoplasms are summarized in Table 2 .
Initial treatment methods for EC
All patients received CRT. They underwent threedimensional conformal radiotherapy. Total radiation dose delivered to the primary tumor and regional lymph node metastases was 60 Gy in 30 fractions (367 patients) or 50.4 Gy in 28 fractions (7 patients). Although 17 patients did not complete CRT, 7 of these 17 patients were given > 50 Gy. In most of these patients, the initial anterior/posterior radiation field included the primary tumor and regional lymph nodes, and a pair of off-cord oblique field was used after irradiation of about 40 Gy. Chemotherapy consisted of 5-fluorouracil (5-FU) + cisplatin, 5-FU + nedaplatin, 5-FU, and others in 307, 57, 19, and 8 patients, respectively. Almost patients were delivered 5-FU+cisplatin as a standard regimen, 5-FU+nedaplatin was selected for the patients with cardiac dysfunction, and 5-FU alone was selected for elderly patients. We delivered 60 Gy even for M1 patients to improve and keep passage of the esophagus as long as possible.
Treatment methods for BM from EC
Twelve patients showed BM. Among the 4 patients with single metastasis, 2 received stereotactic radiotherapy, 1 received stereotactic radiosurgery, and the other received whole-brain radiotherapy (WBRT). Among 8 patients with multiple metastases, 5 received WBRT, 2 underwent surgical resection and WBRT, and the remaining patient received no treatment.
Follow-up procedures and evaluation method
Data were obtained from medical records, computed tomography (CT), and magnetic resonance imaging (MRI). CT or MRI of the brain was performed usually when patients revealed neurological symptoms during follow-up. Conversely, thoracic and abdominal imagings were performed every few months. The patients with BM were categorized using recursive partitioning analysis (RPA). RPA class was indicated by analyzing the results of the Radiation Therapy Oncology Group report, with patients categorized as Class I (Karnofsky PS (KPS) score ≥ 70, age < 65 years, controlled primary tumor, no extracranial metastasis), Class III (KPS score < 70), and Class II (all other patients). 12) Kaplan-Meier methods were used to reveal the cumulative incidence of BM. Cox proportional hazard models were used to analyze risk factors for BM. In the analysis for risk fac- 
Institutional review board
This study protocol was approved by the ethics committee at Shizuoka Cancer Center Hospital.
RESULTS
Frequency and characteristics of BM after CRT for EC
For 391 patients, median follow-up period was 14.6 months (range, 0.4-76.4 months). As of final follow-up, 158 patients were alive and 233 were dead. The overall survival rate after 1 and 3 years were 42% and 19% (median survival: 18.3 months) (Fig. 1) . Metastases to the brain after CRT were found in 12 patients. The 3-year cumulative incidence of BM after CRT for EC was recognized as 6.6% (Fig. 2) . Median interval between first day of CRT and occurrence of BM was 12.1 months (range, 0.3-27.5 months). Fig. 3 shows Fig. 1 . Overall survival rate after chemoradiotherapy for esophageal carcinoma. Table 3 . Other data from patients are arranged in Table 4 . Median age at diagnosis of BM was 64 years (range, 58-77 years). Male to female ratio was 11/1. Initial clinical stage included II, III, and IV in 1, 2, and 9 patients, respectively. Histology included squamous cell carcinoma, adenocarcinoma, and small cell carcinoma in 10, 1, and 1 patient, respectively. RPA classes were II and III in 6 patients each. All patients showed additional evidence of systemic disease.
After treatment for BM, all but 1 patient were free from progression of neurological symptoms until death. This patient showed BM and pleural dissemination when BM was found. Disturbance of consciousness was identified 3 months after treatment for BM, and he detected recurrence of BM and meningeal dissemination. He subsequently died of sepsis. Four patients had single metastasis and 8 had multiple metastases. Median number of BM lesions was 4 (range, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Median size of the largest metastasis for each patient was 2.9 cm (range, 1.4-6.0 cm) ( Table 4) .
Median interval from initial treatment to first recurrence was 8.4 months (range, 0.3-12.2 months). Among the 12 patients, BM appeared as a first recurrence in 4 patients (33%). Median interval between first day of CRT and occurrence of BM was 12.1 months (range, 0.3-27.5 months). All 12 patients had died by final follow-up.
Analysis of risk factors
Among several data, univariate analysis demonstrated M factor as a significant risk factor for BM (P = 0.006), but no other factors were significant (P > 0.05).
Local recurrence was not associated with BM (P > 0.05). On the other hand, distant lymph node relapse, lung metastasis recurrence, and liver metastasis recurrence were significantly related with occurrence of BM (P < 0.05). The results of univariate analysis are shown in Table 5 .
Survival after BM
Median survival time (MST) after diagnosis of BM was 2.1 months (range, 0.2-18.2 months), with 5.5 months (range, 2.5-18.2 months) for single metastasis and 1.2 months (range, 0.2-7.0 months) for multiple metastases. BM was not directly related to cause of mortality. Results of follow-up after treatment are summarized in Table 6 .
DISCUSSION
The increasing incidence of BM may be largely attributable to recent advances in systemic therapy and the greater availability and use of diagnostic imaging. The most common primary site for BM in adults is the lung, followed by the breast. 13) On the other hand, BM from EC is rare. The incidence of BM from EC was 1.4-1.7%. [2] [3] [4] In our study, the crude and 3-year cumulative incidences of BM after CRT were 3.1% (12 of 391 patients) and 6.6%, respectively. This crude rate may be slightly higher than reported previously. We first showed the cumulative incidence, which was about double the crude rate. Patients in our study were all treated by CRT at first treatment. And also our study included 165 patients (42.2%) with primary tumor invaded adjacent structures (T4) or lymph node metastasis (N1), and 162 patients (41.4%) with distant metastasis (M1). However, the treatment methods for EC were not limited to CRT in previous 3) This suggests that the present study included more advanced-stage patients than other studies. The higher incidence of BM would thus be explained by the inclusion of more advanced-stage patients in our study.
Among cases of non-small cell lung cancer, one of the most common primary sites with BM, MST after identification of BM is 5.8-6 months. 14, 15) In cases of breast cancer, MST is 5.5-5.6 months. 16, 17) On the other hand, in our study of EC treated with CRT, MST was 2.1 months. 12) In our study, 6 patients were seen in each of RPA classes II and III, but MST after identification of BM was only 2.1 months. Compared with the report by Gaspar et al., MST in our study was short.
We also reviewed hematological metastases to other main organs. BM was recognized in 8.8% (12 patients) during the study period. This frequency was less than that for the lung, liver, bone, and adrenal gland. Weinberg et al. searched patients with EC (1588 patients) not limited by initial treatment, and reported that the number of BM patients (27 patients) followed the numbers of patients with metastases to the liver (351 patients), lung (245 patients), bone and soft tissue (138 patients), adrenal gland (45 patients), and spine (31 patients).
3) Quint et al. inspected patients with EC (838 patients), likewise finding that the number of BM patients was less than those with metastases to the liver (52 patients), lung (29 patients), bone (13 patients), adrenal gland (8 patients), and peritoneum (3 patients).
18) The frequency of BM appears to be next to that of metastases to the adrenal glands. Findings of BM might be increasing due to regular use of brain imaging studies as well as thoracic and abdominal imaging. However, routine brain imaging for patients with EC may not be clinically worthwhile. In our 12 patients, BM was shown as part of the systemic spread of tumor. The frequency of distant extracerebral lesions was reported as 44-78% at diagnosis of BM. [2] [3] [4] 19) Ogawa et al. reported advanced stage as a possible risk factor for BM. 2) Other recurrence without local recurrence, such as distant lymph node relapse, lung metastasis recurrence, and liver metastasis recurrence, was a significant risk factor for BM in our study. In other words, BM occurred frequently in the presence of active distant extracranial metastasis.
In conclusion, BM from EC was previously considered relatively rare, and the 3-year cumulative incidence rate of BM after CRT for EC was reported as 6.6%. BM may increase in the future with improving survival following EC, but BM was not directly related to causes of mortality. As MST after identification of BM was only 2.1 months, shortterm palliative therapy appears preferable to vigorous longterm therapy.
